Trends in outpatient resource utilizations and outcomes for medicare beneficiaries with nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

Volumn 49, Issue 3, 2015, Pages 222-227

  Younossi, Zobair M ^a,b   Zheng, Li ^b   Stepanova, Maria ^b   Henry, Linda ^a   Venkatesan, Chapy ^a   Mishra, Alita ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Cardiovascular; Medicare; Nonalcoholic liver disease

Indexed keywords

AGED; ARTICLE; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; REIMBURSEMENT; VERY ELDERLY; AGE; AMBULATORY CARE; ECONOMICS; HEALTH CARE COST; HEALTH CARE PLANNING; INSURANCE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TIME; TRENDS; UNITED STATES; UTILIZATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INSURANCE BENEFITS; MALE; MEDICARE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OFFICE VISITS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS; UNITED STATES;

EID: 84922715069     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000071     Document Type: Article

References (35)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, the American Association for the Study of Liver Diseases, American College of Gastroenterology. Gastroenterology. 2012;142:1592-16092.
2. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? Endocr Metab Immune Disord Drug Targets. 2008;8:301-307, Review.
3. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885-904.
4. Sdiri W, Romdhane H, Mbarek D. Non alcoholic fatty liver disease: a new risk factor for cardiovascular disease? Tunis Med. 2013;91:171-174.
5. Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2013;92: 114-118.
6. Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol. 2012;23:345-352.
7. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci. 2012;57:1773-1781.
8. Nseir W, Mahamid M. Statins in non-alcoholic fatty liver disease and steatohepatitis: update review. Curr Atheroscler Rep. 2013;15:305.
9. Nakajima K. Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol. 2012; 2012:950693.
10. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
11. Koebnick C, Getahun D, Reynolds K. Coleman Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. J Pediatr Gastroenterol Nutr. 2009;48:597-603.
12. Bellentani S, Scaglioni F, Marion M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
13. Quercioli A, Montecucco F, Pataky Z. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J. 2013;34:2063-2073.
14. Targher G, Arcaro G. Non alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-240.
15. Hamaguchi M, Kojima T, Takeda N. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-728.
16. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2007;13:3540-3553, Review.
17. Basaranoglu M, Kayacetin S, Yilmaz N, et al. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:2223-2226.
18. Laurin J, Lindor KD, Crippin JS. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464-1467.
19. Rallidis LS, Kotakos C, Sourides V. Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dL and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. Expert Opin Pharmacother. 2011;12:1481-1489.
20. Marchesini G, Natale S, Manini R, et al. Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther. 2005;22(suppl 2):37-39, Review.
21. Nair S. Nonalcoholic Fatty liver disease from the perspective of an internist. Ochsner J. 2002;4:92-97.
22. Assy N, Grozovski M, Bersudsky I, et al. Effect of insulinsensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol. 2006;12:4369-4376.
23. Promrat K, Lutchman G, Uwaifo GI. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196.
24. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev. 2009;10:412-419.
25. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012;2012:483135.
26. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646-650.
27. Dam-Larsen S, Becker U, Franzmann MB, et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44:1236-1243.
28. Lazo M, Hernaez R, Bonekamp S. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:d6891.
29. Monami M, Bardini G, Lamanna C. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 2008;57:387-392.
30. Ioannou GN,Weiss NS, Boyko EJ, et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006;43:1145-1151.
31. Ló pez-Suá rez A, Guerrero JM, Elvira-Gonzá lez J, et al. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol. 2011;23:1011-1017.
32. Yong-Fang K, Goodwin J. Impact of hospitalists on length of stay in the medicare population: variation by hospital and patient characteristics. J Am Geriatr Soc. 2010;58:1649-1657.
33. Coughlin TA, Waidmann TA, Phadera L. Among dual eligibles, identifying the highest-cost individuals could help in crafting more targeted and effective responses. Health Aff (Millwood). 2012;31:1083-1091.
34. Bubolz T, Emerson C, Skinner J. State spending on dual eligibles under age 65 shows variations, evidence of cost shifting from Medicaid to Medicare. Health Aff (Millwood). 2012;31:939-947.
35. Younossi Z, Gramlich T, Matteoni C, et al. Non-alcoholic fatty liver disease in patients with Type II diabetes. Clin Gastroenterol Hepatol. 2004;2:262-265.